Literature DB >> 24739327

Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody.

Jing Zou1, Ting Li2, Xingfang Huang2, Sheng Chen2, Qiang Guo2, Chunde Bao2.   

Abstract

Entities:  

Keywords:  Autoimmune Diseases; Dermatomyositis; T Cells

Mesh：

Substances：

Year:  2014        PMID： 24739327     DOI： 10.1136/annrheumdis-2014-205278

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  21 in total

Review 1.  A new look at rheumatology in China--opportunities and challenges.

Authors:  Zhan-Guo Li
Journal:  Nat Rev Rheumatol       Date:  2015-01-20       Impact factor: 20.543

Review 2.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

Review 3.  Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.

Authors:  Roberta Vilela Lopes Koyama; Tiago Kiyoshi Kitabayashi Braga; George Alberto da Silva Dias; Satomi Fujihara; Hellen Thais Fuzii; Gilberto Toshimitsu Yoshikawa
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

4.  Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum.

Authors:  Xiaolei Ma; Zhiyong Chen; Wei Hu; Ziwei Guo; Yan Wang; Masataka Kuwana; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2015-07-07       Impact factor: 2.980

Review 5.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

6.  Decreased Th1 Cells and Increased Th2 Cells in Peripheral Blood Are Associated with Idiopathic Inflammatory Myopathies Patients with Interstitial Lung Disease.

Authors:  Lu Cheng; Yanhong Li; Yubin Luo; Yu Zhou; Ji Wen; Yinlan Wu; Xiuping Liang; Tong Wu; Chunyu Tan; Yi Liu
Journal:  Inflammation       Date:  2022-10-20       Impact factor: 4.657

Review 7.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 8.  Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

Authors:  Rachel Zeng; Stefanie Glaubitz; Jens Schmidt
Journal:  Neurotherapeutics       Date:  2022-04-08       Impact factor: 6.088

9.  The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.

Authors:  Takeshi Osawa; Kozo Morimoto; Yuka Sasaki; Shuichi Matsuda; Kazunari Yamana; Ryozo Yano; Takashi Uchiyama; Hajime Goto
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

10.  Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.

Authors:  Ting Li; Li Guo; Zhiwei Chen; Liyang Gu; Fangfang Sun; Xiaoming Tan; Sheng Chen; Xiaodong Wang; Shuang Ye
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.